Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clopidogrel Tablets Clear all
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
View directory record Official record
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

NCT01129427
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Pantoprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

NCT05162053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
vicagrel Capsules, Clopidogrel Tablets
Drug
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
Interventions
Rivaroxaban 2.5 mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants

NCT07619885
View directory record Official record
Conditions
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
Interventions
CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
Drug
Lead sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Withdrawn Phase 2 Interventional

Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant

NCT02008123
View directory record Official record
Conditions
Clopidogrel Resistance, Secondary Stroke Prevention
Interventions
Primidone
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

NCT00642174
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
View directory record Official record
Conditions
Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Interventions
Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Edoxaban in Peripheral Arterial Disease

NCT01802775
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
edoxaban, Clopidogrel, Aspirin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

NCT01523366
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Hollywood, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

NCT00650169
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Withdrawn Phase 4 Interventional

Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

NCT00589862
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Plavix (Clopidogrel)
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Tailored Antiplatelet Therapy Following PCI

NCT01742117
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 4 Interventional Results available

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635
View directory record Official record
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

NCT00648947
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 5:31 PM EDT